“They could probably pay for it out of internal cash flow,” said a loans banker close to the borrower. “They have time so they will probably do a bond issue.”
Teva recorded record annual cash flow of $4.1bn for 2010, up from $3.4bn in 2009.Teva and Cephalon announced the ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com